VEGFA and angiosarcoma: In contrast, our data revealed an apparent IC50 of 8 μM for fenofibrate’s anti-proliferative action in MS1 VEGF angiosarcoma cells (Fig. 1e), which fits well with the plasma concentrations reported in clinical use36,37.